Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials
In 2022, the FDA placed Sanofi’s Phase 3 studies of tolebrutinib in multiple sclerosis and myasthenia gravis on partial ...
pharmaphorum6d
Sanofi's tolebrutinib cuts MS progression by 31% in trial
Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...
Reuters1mon
Denali-Sanofi scraps mid-stage study for multiple sclerosis drug
Multiple sclerosis is a debilitating neurological condition where the immune system degrades the protective covering of nerves. The drug candidate, oditrasertib, co-developed by Sanofi and Denali ...
pharmaphorum1d
Two of three trials fail, but Sanofi will still file MS drug
Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...
Business Insider7m
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
About Sanofi/Novartis litigation On March 30,2022 ... and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and ...
Seeking Alpha1mon
Sanofi, Denali face another mid-stage setback for neurology therapy
which was designed to evaluate DNL788 in patients with multiple sclerosis. The company added that the trial failed to achieve primary and key secondary endpoints, and as a result, Sanofi (SNY ...
Managed Healthcare Executive7d
Sanofi Ends Trial of Oditrasertib
Drugmakers had hoped that inhibiting receptor-interacting protein kinase would decrease inflammation and reduce neuronal degeneration in patients with multiple sclerosis and other neurodegenerative co ...
FierceBiotech6d
ASH: Sanofi's BTK inhibitor raises platelet levels in 23% of ITP patients in phase 3
Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...
Medscape1mon
Multiple Sclerosis News
Exclusive-Teva Faces EU Fine for Disparaging Rival Multiple Sclerosis Medicine, Sources Say Teva, the world's largest generic drugmaker, will be hit with an EU antitrust fine in the coming weeks ...
Yahoo Finance21d
Sanofi and CD&R enter exclusive talks for Opella sale
Sanofi’s decision to enter this partnership ... concentrating on addressing significant health issues such as RSV, COPD, and multiple sclerosis. This transaction would also enable Opella to ...
Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcareSanofi and CD&R enter exclusive negotiations to transfer a 50% ...